{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:14:17Z","timestamp":1780946057723,"version":"3.54.1"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.cellimm.2018.10.003","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T20:55:27Z","timestamp":1539377727000},"page":"87-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The challenges of checkpoint inhibition in the treatment of multiple myeloma"],"prefix":"10.1016","volume":"334","author":[{"given":"Barry","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2018.10.003_b0005","unstructured":"Surveillance Research Program, N. C. I. Fast Stats: An interactive tool for access to SEER cancer statistics, <https:\/\/seer.cancer.gov\/faststats>, 2018."},{"issue":"Suppl 1","key":"10.1016\/j.cellimm.2018.10.003_b0010","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1002\/ana.410370705","article-title":"Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies","volume":"37","author":"Latov","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.ackd.2012.04.009","article-title":"The pathogenesis of acute kidney impairment in patients with multiple myeloma","volume":"19","author":"Batuman","year":"2012","journal-title":"Adv. Chron. Kidney Dis."},{"key":"10.1016\/j.cellimm.2018.10.003_b0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1477-7819-12-234","article-title":"Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study","volume":"12","author":"Zhang","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0025","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12478","article-title":"Clinical course and prognosis of non-secretory multiple myeloma","author":"Chawla","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0030","doi-asserted-by":"crossref","unstructured":"R. Fonseca, International Myeloma Working Group molecular classification of multiple myeloma: spotlight review, 23 (2009) 2210\u20132221, doi: 10.1038\/leu.2009.174.","DOI":"10.1038\/leu.2009.174"},{"key":"10.1016\/j.cellimm.2018.10.003_b0035","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0040","doi-asserted-by":"crossref","unstructured":"P. Wijermans, et al., Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study, J. Clin. Oncol., doi:JCO.2009.26.1610 [pii] 10.1200\/JCO.2009.26.1610.","DOI":"10.1200\/JCO.2009.26.1610"},{"key":"10.1016\/j.cellimm.2018.10.003_b0045","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0050","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0060","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0065","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0070","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0075","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0080","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","article-title":"Survival and years of life lost in different age cohorts of patients with multiple myeloma","volume":"28","author":"Ludwig","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0090","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0095","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0100","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0105","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b\u20132 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0120","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cellimm.2018.10.003_b0125","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8516","article-title":"Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial","volume":"27","author":"Knop","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0130","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","article-title":"Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients","volume":"28","author":"Palumbo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0140","unstructured":"S.K. Kumar et al., Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study, Leukemia, doi:leu2010116 [pii] 10.1038\/leu.2010.116."},{"key":"10.1016\/j.cellimm.2018.10.003_b0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","article-title":"Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer","volume":"11","author":"Drake","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/cancers8120106","article-title":"Advances in cancer immunotherapy in solid tumors","volume":"8","author":"Menon","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.cellimm.2018.10.003_b0155","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2018.10.003_b0160","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0165","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2016.152504","article-title":"Is immunotherapy here to stay in multiple myeloma?","volume":"102","author":"Rodriguez-Otero","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.cellimm.2018.10.003_b0170","first-page":"4472","article-title":"T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression","volume":"7","author":"June","year":"1987","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0175","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.169.3950.1042","article-title":"A theory of self-nonself discrimination","volume":"169","author":"Bretscher","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2018.10.003_b0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev.iy.07.040189.002305","article-title":"Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy","volume":"7","author":"Mueller","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0185","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/icb.1975.3","article-title":"A new analysis of allogeneic interactions","volume":"53","author":"Lafferty","year":"1975","journal-title":"Aust. J. Exp. Biol. Med. Sci."},{"key":"10.1016\/j.cellimm.2018.10.003_b0190","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1073\/pnas.87.13.5031","article-title":"T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1","volume":"87","author":"Linsley","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cellimm.2018.10.003_b0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2018.10.003_b0200","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0205","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/366076a0","article-title":"B70 antigen is a second ligand for CTLA-4 and CD28","volume":"366","author":"Azuma","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2018.10.003_b0210","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.7694361","article-title":"Identification of an alternative CTLA-4 ligand costimulatory for T cell activation","volume":"262","author":"Hathcock","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2018.10.003_b0215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0220","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20150435","article-title":"Btn2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes","author":"Sarter","year":"2016","journal-title":"J. Exp. Med. JEM"},{"key":"10.1016\/j.cellimm.2018.10.003_b0225","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.4049\/jimmunol.0902937","article-title":"T cell Ig and mucin domain proteins and immunity","volume":"184","author":"Kane","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0230","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1300945","article-title":"The CD226\/CD155 interaction regulates the proinflammatory (Th1\/Th17)\/anti-inflammatory (Th2) balance in humans","author":"Lozano","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0235","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/485781","article-title":"Positive and negative regulation of cellular immune responses in physiologic conditions and diseases","volume":"2012","author":"Vigano","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0240","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.immuni.2011.04.008","article-title":"Cell surface signaling molecules in the control of immune responses: a tide model","volume":"34","author":"Zhu","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2018.10.003_b0245","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1016\/j.febslet.2010.11.036","article-title":"Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters","volume":"584","author":"Saito","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cellimm.2018.10.003_b0250","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.immuni.2010.09.006","article-title":"Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation","volume":"33","author":"Yokosuka","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2018.10.003_b0255","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0260","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1034\/j.1600-065X.2003.00022.x","article-title":"Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors","volume":"192","author":"Saito","year":"2003","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2018.10.003_b0265","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.172.7.4100","article-title":"Ligation of B7\u20131\/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells","volume":"172","author":"Munn","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0270","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0275","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7\u2013H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0280","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12185-018-2405-7","article-title":"Immunopathogenesis and immunotherapy of multiple myeloma","volume":"107","author":"Tamura","year":"2018","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0285","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0290","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"El-Sherbiny","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0295","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00262-009-0807-3","article-title":"Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked","volume":"59","author":"von Lilienfeld-Toal","year":"2010","journal-title":"Cancer Immunol. Immunother.:CII"},{"key":"10.1016\/j.cellimm.2018.10.003_b0300","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.cellimm.2018.10.003_b0305","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0310","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0315","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"158","author":"Kim","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0320","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3138.3138","article-title":"Neutrophils Of multiple myeloma are dysfunctional and immunosuppressive","volume":"122","author":"Parrinello","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0325","article-title":"Induction of malignant plasma cell proliferation by eosinophils","volume":"8","author":"Wong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2018.10.003_b0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109018","article-title":"Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches","volume":"9","author":"Wong","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2018.10.003_b0335","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalhaes","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.cellimm.2018.10.003_b0340","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.1983.tb02021.x","article-title":"Abnormal monoclonal antibody-defined helper\/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage","volume":"53","author":"Mills","year":"1983","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0345","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10245330310001652437","article-title":"Th1\/Th2 cells in patients with multiple myeloma","volume":"9","author":"Murakami","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.cellimm.2018.10.003_b0350","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0355","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0360","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0365","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies","volume":"117","author":"Korde","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0370","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.2011.575","article-title":"The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma","volume":"106","author":"Giannopoulos","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellimm.2018.10.003_b0375","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2018.10.003_b0380","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","article-title":"Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0385","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7\u20131) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0390","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellimm.2018.10.003_b0395","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0400","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cellimm.2018.10.003_b0405","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0410","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2059.2059","article-title":"Immune checkpoint blockade combinations as promising strategy for cancer immunotherapy in multiple myeloma patients","volume":"128","author":"Castella","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0415","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1158\/1078-0432.CCR-07-5290","article-title":"Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy","volume":"14","author":"Song","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0420","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0425","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4106.4106","article-title":"Increased M2 macrophages in multiple myeloma patients with progressive disease and down-regulated polarization with the JAK2 inhibitor ruxolitinib","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0430","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00262-014-1623-y","article-title":"Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells","volume":"64","author":"Andr\u00e9","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cellimm.2018.10.003_b0435","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0440","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2018.10.003_b0445","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2018.10.003_b0450","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2018.10.003_b0455","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0460","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.11577","article-title":"Function and expression of checkpoint inhibitors and immune agonists on immune cells in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and MM and tumor-specific T lymphocytes","volume":"35","author":"Bae","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0465","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7\u2013H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.cellimm.2018.10.003_b0470","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0475","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.cellimm.2018.10.003_b0480","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol. Blood Marrow Trans."},{"key":"10.1016\/j.cellimm.2018.10.003_b0485","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7\u2013H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0490","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7\u2013H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cellimm.2018.10.003_b0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2018.10.003_b0500","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","article-title":"PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2","volume":"32","author":"Carter","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0505","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/2326-6066.CIR-15-0296","article-title":"Myeloma Drug Resistance Induced by Binding of Myeloma B7\u2013H1 (PD-L1) to PD-1","volume":"4","author":"Ishibashi","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0510","doi-asserted-by":"crossref","first-page":"62490","DOI":"10.18632\/oncotarget.11519","article-title":"Soluble PD-L1: a biomarker to predict progression of autologous transplantation in patients with multiple myeloma","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellimm.2018.10.003_b0515","doi-asserted-by":"crossref","first-page":"41228","DOI":"10.18632\/oncotarget.5682","article-title":"Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellimm.2018.10.003_b0520","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/bjc.2013.117","article-title":"Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer","volume":"108","author":"Quezada","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellimm.2018.10.003_b0525","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2217\/imt.15.57","article-title":"Antibody-based immunotherapy of solid cancers: progress and possibilities","volume":"7","author":"Nicodemus","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cellimm.2018.10.003_b0530","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety & tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0535","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0540","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0545","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0550","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0555","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0560","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0565","unstructured":"V. Ribrag, et al., Pembrolizumab Monotherapy for Relapsed\/Refractory Multiple Myeloma (RRMM): Phase 1b Keynote-013 Study 2017, EHA EHA Learning Center."},{"key":"10.1016\/j.cellimm.2018.10.003_b0570","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0575","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol. Immunother.: CII"},{"key":"10.1016\/j.cellimm.2018.10.003_b0580","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.492.492","article-title":"Lenalidomide decreases PD-1 expression, depletes regulatory T-cells and improves cellular response to a multiple myeloma\/dendritic cell fusion vaccine in vitro","volume":"116","author":"Luptakova","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0585","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/10428194.2017.1320713","article-title":"Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma","volume":"59","author":"Pianko","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cellimm.2018.10.003_b0590","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0595","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8015","article-title":"Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed\/refractory multiple myeloma (RRMM): efficacy and biomarker analyses","volume":"35","author":"Ocio","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0600","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8021","article-title":"A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed\/refractory multiple myeloma (RRMM): KEYNOTE-183","volume":"36","author":"Mateos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0605","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8008","article-title":"FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response","volume":"36","author":"Krauss","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0610","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8010","article-title":"A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185","volume":"36","author":"Usmani","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0615","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0620","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0625","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0630","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0635","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3102","article-title":"Nivolumab in combination with daratumumab, with or without pomalidomide and dexamethasone, for relapsed\/refractory multiple myeloma: 2 cohorts of the phase 1 CheckMate 039 safety study","volume":"35","author":"Lesokhin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0640","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8052","article-title":"CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma","volume":"35","author":"Lonial","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0645","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/bloodadvances.2017004382","article-title":"PD-1 blockade enhances elotuzumab efficacy in mouse tumor models","volume":"1","author":"Bezman","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.cellimm.2018.10.003_b0650","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8054","article-title":"Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM)","volume":"35","author":"Richardson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0655","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0660","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.cellimm.2018.10.003_b0665","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2018.10.003_b0670","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cellimm.2018.10.003_b0675","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0680","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1807852","article-title":"PD-1 inhibitor therapy in adult T-cell leukemia-lymphoma","volume":"379","author":"Ishitsuka","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2018.10.003_b0685","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2018.10.003_b0690","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2018.10.003_b0695","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2018.10.003_b0700","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.903.903","article-title":"Tackling early morbidity and mortality in myeloma (TEAMM): assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections in 977 patients","volume":"130","author":"Drayson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0705","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.09.013","article-title":"Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1\/2 trial","volume":"68","author":"Levy","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cellimm.2018.10.003_b0710","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2018.10.003_b0715","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","article-title":"A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma","volume":"96","author":"Hiniker","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cellimm.2018.10.003_b0720","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918768240","article-title":"Radiotherapy and checkpoint inhibitors: a winning new combination?","volume":"10","author":"Ko","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0725","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","article-title":"Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0730","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2217\/imt.13.96","article-title":"Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?","volume":"5","author":"Garcia-Marquez","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cellimm.2018.10.003_b0735","first-page":"409","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J. Immunother. (Hagerstown, Md.: 1997)"},{"key":"10.1016\/j.cellimm.2018.10.003_b0740","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11899-015-0283-0","article-title":"Immunotherapy for multiple myeloma, past, present, and future: monoclonal antibodies, vaccines, and cellular therapies","volume":"10","author":"Karp Leaf","year":"2015","journal-title":"Curr. Hematol. Malig Rep."},{"key":"10.1016\/j.cellimm.2018.10.003_b0745","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0750","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0755","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjh.13976","article-title":"The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma","volume":"173","author":"Rotolo","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0760","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8007","article-title":"bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma: updated results from a multicenter phase I study","volume":"36","author":"Raje","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0765","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3001","article-title":"Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory\/relapsed multiple myeloma","volume":"35","author":"Fan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0770","author":"Cohen","year":"2017","journal-title":"Am. Soc. Hematol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0775","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0780","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2018.10.003_b0785","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-014-0043-z","article-title":"Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma","volume":"3","author":"Jing","year":"2015","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.cellimm.2018.10.003_b0790","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8+ T cell immunity against multiple myeloma","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0795","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2102.2102","article-title":"Tigit, CD226 and PD-L1\/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma","volume":"128","author":"Yadav","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2018.10.003_b0800","article-title":"A RIPK3-PGE2 circuit mediates myeloid-derived suppressor cell-potentiated colorectal carcinogenesis","author":"Yan","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0805","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccell.2016.05.012","article-title":"Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy","volume":"30","author":"Hou","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellimm.2018.10.003_b0810","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1158\/1078-0432.CCR-14-0635","article-title":"Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity","volume":"20","author":"Mao","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0815","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function","volume":"10","author":"Veltman","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cellimm.2018.10.003_b0820","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2018.10.003_b0825","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cellimm.2018.10.003_b0830","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-016-0194-1","article-title":"A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma","volume":"4","author":"Brohl","year":"2016","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.cellimm.2018.10.003_b0835","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10147-017-1122-1","article-title":"Biomarkers to predict prognosis and response to checkpoint inhibitors","volume":"22","author":"Yuasa","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0840","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918768238","article-title":"Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice","volume":"10","author":"Boutsikou","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.cellimm.2018.10.003_b0845","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","article-title":"Biomarkers associated with checkpoint inhibitors","volume":"27","author":"Manson","year":"2016","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874918304647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874918304647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:58:53Z","timestamp":1757804333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874918304647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":169,"alternative-id":["S0008874918304647"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2018.10.003","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenges of checkpoint inhibition in the treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2018.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}